It has been demonstrated that anti-idiotypic antibody vaccines against melanoma can mimic tumor-associated antigens and activate anti-tumor immune responses in many animal models and clinical trials.

This paper reviews current advances in the preparation and the clinical application of dendritic cell-based tumor vaccines for tumor immunotherapy.

Conclusion T739 mouse bladder cancer cell lines and tumor-bear model expressing human MUC1 were successfully established for the development of tumor vaccines targeting MUC1.